Who is sponsoring NCT03776903?

NCT03776903 is sponsored by InBios International, Inc..

What drugs are being tested in NCT03776903?

Interventions in NCT03776903: ZIKV Detect™ 2.0 IgM Capture ELISA.

What condition does NCT03776903 study?

NCT03776903 studies Zika Virus Infection.

Is NCT03776903 still recruiting?

NCT03776903 is currently completed. Last updated 17 December 2018.

Last reviewed 2018-12-17 · How we verify

NCT03776903

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA

Completed Last updated 17 December 2018

What this trial tests

trial testing ZIKV Detect™ 2.0 IgM Capture ELISA in Zika Virus Infection in 600 participants. Completed in 30 September 2018.

Timeline

1 April 2018

Primary endpoint
31 August 2018

30 September 2018

Quick facts

Lead sponsor	InBios International, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	600
Start date	1 April 2018
Primary completion	31 August 2018
Estimated completion	30 September 2018
Sites	1 location across United States

Drugs / interventions tested

ZIKV Detect™ 2.0 IgM Capture ELISA

Conditions studied

Zika Virus Infection — all drugs for Zika Virus Infection →

Sponsor

InBios International, Inc.

Who can join

Eligibility, any sex, with Zika Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the performance of the ZIKV Detect™ 2.0 IgM Capture ELISA using archived confirmed ZIKV positive and confirmed ZIKV negative human serum samples.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Zika Virus Infection

Currently open trials in the same condition.

NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting

Other InBios International, Inc. trials

Trials by the same sponsor.

NCT06734741 — Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-t · completed
NCT04320485 — Evaluation of the Clinical Specificity of the Active Anthrax Detect™ Plus (AAD Plus) Lateral Flow Immunoassay (LFI) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03776903 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by InBios International, Inc.
Last refreshed: 17 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03776903.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing